BioXcel Therapeutics (BTAI) Non-Current Assets (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Non-Current Assets of $117000.0 for Q1 2026, down 85.17% year-over-year from $789000.0 in Q1 2025, and down 49.35% quarter-over-quarter from $231000.0 in Q4 2025.
BioXcel Therapeutics (BTAI) Non-Current Assets (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Non-Current Assets history runs 10 years deep, the most recent figure standing at $117000.0 for Q1 2026.
- In Q1 2026, Non-Current Assets fell 85.17% year-over-year to $117000.0; the TTM figure through Mar 2026 stood at $1.3 million (down 68.61% YoY), while the FY2025 annual figure was $231000.0, down 75.53% from the prior year.
- Non-Current Assets for Q1 2026 stood at $117000.0, down from $231000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $3.5 million in Q1 2022, with the low at $117000.0 in Q1 2026.
- The 5-year median for Non-Current Assets is $1.4 million (2024), against an average of $1.6 million.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets grew 13.63% in 2022, then plunged 85.17% in 2026.
- BioXcel Therapeutics' Non-Current Assets stood at $3.0 million in 2022, then slumped by 47.77% to $1.6 million in 2023, then tumbled by 39.45% to $944000.0 in 2024, then sank by 75.53% to $231000.0 in 2025, then sank by 49.35% to $117000.0 in 2026.
- Business Quant data shows BTAI's Non-Current Assets at $117000.0 in Q1 2026, $231000.0 in Q4 2025, and $389000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | BioXcel Therapeutics | 24.29 Mn | 24.29 Mn | 160,000.00 | 99,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99,000.00 |
| Mar 31, 2026 | 117,000.00 |
| Dec 31, 2025 | 231,000.00 |
| Sep 30, 2025 | 389,000.00 |
| Jun 30, 2025 | 546,000.00 |
| Mar 31, 2025 | 789,000.00 |
| Dec 31, 2024 | 944,000.00 |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.25 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.56 Mn |
| Sep 30, 2023 | 1.71 Mn |
| Jun 30, 2023 | 1.86 Mn |
| Mar 31, 2023 | 2.84 Mn |
| Dec 31, 2022 | 2.99 Mn |
| Sep 30, 2022 | 3.16 Mn |
| Jun 30, 2022 | 3.31 Mn |
| Mar 31, 2022 | 3.48 Mn |
| Dec 31, 2021 | 2.63 Mn |
| Sep 30, 2021 | 4.40 Mn |